Key facts
- Restera’s last known valuation is $67.8M (Jul 2025).
- It has raised $69.8M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Eclipse Capital, Eclipse Ventures, GreatPoint Ventures, ShangBay Capital, DNS Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Restera
- ·The full record, as it builds
Funding rounds
No funding rounds for Restera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Restera
Developer of an injectable neurostimulation device designed to provide a novel and less intrusive treatment for obstructive sleep apnea. The company offers a clinical-stage medical device with a micro injectable neurostimulation approach, opening collapsed airways, enabling patients with sleep apnea to achieve peaceful and restorative sleep while reducing the risk of serious health complications.
- Sector
- Healthcare
- HQ
- Santa Clara, CA, United States
- Founded
- 2013
- Employees
- 12
- Website
- resterasleep.com/
- Ownership
- Privately Held (backing)
Restera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Restera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Restera in its N-PORT filings yet. We sweep new filings monthly.